Abstract
Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
Original language | English (US) |
---|---|
Pages (from-to) | 261-267 |
Number of pages | 7 |
Journal | Diabetes and Metabolism |
Volume | 22 |
Issue number | 4 |
State | Published - Jul 1 1996 |
Externally published | Yes |
Keywords
- Type 2 diabetes mellitus
- growth hormone
- insulin resistance
- insulin sensitivity
- insulin-like growth factor-I
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology